This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
UPF3A · Western blot design guide
UPF3A Western Blot Planning Guide
Plan an UPF3A Western blot around the catalog-observed 54.7 kDa band, image-backed A08388-2 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
UPF3A Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 54.7 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 12-15% | |
| Positive control | Testis | |
| Negative control | Heart muscle |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 54.7 kDa |
| ⓘ | Localization | Nucleus / Cytoplasm |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated UPF3A Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Bronchus |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A08388-2 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected UPF3A Western Blot Band Size?
Use the product-observed 54.7 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 54.7 kDa | Matches the authoritative product WB observation. |
| 54.7 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected UPF3A appearancePlan around 54.7 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 54.7 kDa; use this as the primary experimental expectation. |
| Calculated mass | 54.7 kDa from UniProt Q9H1J1; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A08388-2. |
| Situation | Likely cause | Next action |
|---|---|---|
| 54.7 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing UPF3A band
A08388-2 · UPF3A
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for UPF3A Western blot
🧪Use Testis as the first positive-control candidate and Heart muscle as the HPA Not detected negative candidate.
Positive control: Testis (High)
Negative control: Heart muscle (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for UPF3A
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Testis | Reported tissue cells | High | Protein (HPA) | HPA → |
| Bronchus | Reported tissue cells | High | Protein (HPA) | HPA → |
| Nasopharynx | Reported tissue cells | High | Protein (HPA) | HPA → |
| Adrenal gland | Reported tissue cells | Medium | Protein (HPA) | HPA → |
Section 3
Advanced UPF3A Western Blot Tips
Deeper troubleshooting and optimisation questions for UPF3A, answered from its protein features.
Which band should guide the blot?
Use 54.7 kDa, the observation attached to the authoritative A08388-2 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 54.7 kDa expectation.
Which positive control should I start with?
Start with Testis, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Heart muscle as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for UPF3A Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A08388-2 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
UPF3A Western Blot Reagents
Human/Mouse/Rat-reactive UPF3A Western blot reagents with authoritative product imagery.
Real WB data
Anti-UPF3A Antibody Picoband®
Cat # A08388-2
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt Q9H1J1
- Human Protein Atlas — UPF3A
- A08388-2 product record
- PMC7432364 — (Phospho)proteomic Profiling of Microsatellite Unstable CRC Cells Reveals Alterations in Nuclear Signaling and Cholesterol Metabolism Caused by Frameshift Mutation of NMD Regulator UPF3A (International journal of molecular sciences, 2020)
- PMC10070813 — UPF3A is dispensable for nonsense-mediated mRNA decay in mouse pluripotent and somatic cells (Life science alliance, 2023)
- PMC9108619 — Human UPF3A and UPF3B enable fault-tolerant activation of nonsense-mediated mRNA decay (The EMBO journal, 2022)